Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies

Apoptosis

Volumn 23, Issue 2, 2018, Pages 93-112

  Razaghi, Ali ^a   Heimann, Kirsten ^a   Schaeffer, Patrick M ^a   Gibson, Spencer B ^b,c  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Biomarker; Cancer targeted therapy; Cell death pathway; Drug resistance; Immunotherapy; Negative regulator

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELL FREE NUCLEIC ACID; EPIDERMAL GROWTH FACTOR BASED VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN BASED VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BNIP3; PROTEIN KINASE B; SURVIVIN; SURVIVIN BASED VACCINE; TRANSCRIPTION FACTOR SIX1; UNCLASSIFIED DRUG; VACCINE; TUMOR MARKER;

ANOIKIS; APOPTOSIS; AUTOPHAGY; CANCER IMMUNOTHERAPY; CELL DEATH; CLINICAL OUTCOME; FERROPTOSIS; HUMAN; MOLECULARLY TARGETED THERAPY; NECROPTOSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; GENETICS; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; APOPTOSIS; AUTOPHAGY; BIOMARKERS, TUMOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85040345199     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-018-1440-4     Document Type: Review

References (142)

1. Biemar F, Foti M (2013) Global progress against cancer-challenges and opportunities. Cancer Biol Med 10:183–186. https://doi.org/10.7497/j.issn.2095-3941.2013.04.001
2. Huang M, Shen A, Ding J, Geng M (2014) Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 35:41–50. https://doi.org/10.1016/j.tips.2013.11.004
3. Lambert G, Estevez-Salmeron L, Oh S et al (2011) An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer 11:375–382. https://doi.org/10.1038/nrc3039
4. Housman G, Byler S, Heerboth S et al (2014) Drug resistance in cancer: an overview. Cancers 6:1769–1792. https://doi.org/10.3390/cancers6031769
5. Hata AN, Engelman JA, Faber AC (2015) The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov 5:475–487. https://doi.org/10.1158/2159-8290.CD-15-0011
6. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
7. Garraway LA, Janne PA (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2:214–226. https://doi.org/10.1158/2159-8290.CD-12-0012
8. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87. https://doi.org/10.1186/1756-9966-30-87
9. Kasibhatla S, Tseng B (2003) Why target apoptosis in cancer treatment? Mol Cancer Ther 2:573–580
10. Xie Y, Hou W, Song X et al (2016) Ferroptosis: process and function. Cell Death Differ 23:369–379. https://doi.org/10.1038/cdd.2015.158
11. Razaghi A, Owens L, Heimann K (2016) Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J Biotechnol 240:48–60. https://doi.org/10.1016/j.jbiotec.2016.10.022
12. Lee HJ, Kim JY, Park JE, Yoon YD, Tsang BK, Kim JM (2016) Induction of Fas-mediated apoptosis by interferon-gamma is dependent on granulosa cell differentiation and follicular maturation in the rat ovary. Dev Reprod 20:315–329. https://doi.org/10.12717/DR.2016.20.4.315
13. Razaghi A, Villacres C, Jung V et al (2017) Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells. Exp Cell Res 359:20–29. https://doi.org/10.1016/j.yexcr.2017.08.014
14. Guicciardi ME, Gores GJ (2009) Life and death by death receptors. FASEB J 23:1625–1637. https://doi.org/10.1096/fj.08-111005
15. Iyer S, Bell F, Westphal D et al (2015) Bak apoptotic pores involve a flexible C-terminal region and juxtaposition of the C-terminal transmembrane domains. Cell Death Differ 22:1665–1675. https://doi.org/10.1038/cdd.2015.15
16. Pobezinskaya YL, Liu Z (2012) The role of TRADD in death receptor signaling. Cell Cycle 11:871–876. https://doi.org/10.4161/cc.11.5.19300
17. Allen JE, Kline CL, Prabhu VV et al (2016) Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7:74380–74392. https://doi.org/10.18632/oncotarget.11814
18. von Karstedt S, Conti A, Nobis M et al (2015) Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 27:561–573. https://doi.org/10.1016/j.ccell.2015.02.014
19. Chen L, Park SM, Tumanov AV et al (2010) CD95 promotes tumour growth. Nature 465:492–496. https://doi.org/10.1038/nature09075
20. Hartwig T, Montinaro A, von Karstedt S et al (2017) The TRAIL-Induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell 65:730–742 e735. https://doi.org/10.1016/j.molcel.2017.01.021
21. Shirley S, Micheau O (2013) Targeting c-FLIP in cancer. Cancer Lett 332:141–150. https://doi.org/10.1016/j.canlet.2010.10.009
22. Fox JL, MacFarlane M (2016) Targeting cell death signalling in cancer: minimising ‘Collateral damage’. Br J Cancer 115:5–11. https://doi.org/10.1038/bjc.2016.111
23. Lemke J, von Karstedt S, Zinngrebe J, Walczak H (2014) Getting TRAIL back on track for cancer therapy. Cell Death Differ 21:1350–1364. https://doi.org/10.1038/cdd.2014.81
24. Lee EW, Seo J, Jeong M, Lee S, Song J (2012) The roles of FADD in extrinsic apoptosis and necroptosis. BMB Rep 45:496–508. https://doi.org/10.5483/BMBRep.2012.45.9.186
25. Zhang Y, Zhu J, Tang Y et al (2011) X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol 6:49. https://doi.org/10.1186/1746-1596-6-49
26. Lafont E, Kantari-Mimoun C, Draber P et al (2017) The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J 36:1147–1166. https://doi.org/10.15252/embj.201695699
27. Probst BL, Liu L, Ramesh V et al (2010) Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 17:1645–1654. https://doi.org/10.1038/cdd.2010.44
28. Vamos M, Welsh K, Finlay D et al (2013) Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol 8:725–732. https://doi.org/10.1021/cb3005512
29. Fenstermaker RA (2014) Survivin as a cancer vaccine target. J Vaccines Vaccin. https://doi.org/10.4172/2157-7560.1000230
30. Ausserlechner MJ, Hagenbuchner J (2016) Mitochondrial survivin—an Achilles’ heel in cancer chemoresistance. Mol Cell Oncol 3:e1076589. https://doi.org/10.1080/23723556.2015.1076589
31. Pan R, Hogdal LJ, Benito JM et al (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:362–375. https://doi.org/10.1158/2159-8290.CD-13-0609
32. Cang S, Iragavarapu C, Savooji J, Song Y, Liu D (2015) ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol 8:129. https://doi.org/10.1186/s13045-015-0224-3
33. Rudin CM, Hann CL, Garon EB et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18:3163–3169. https://doi.org/10.1158/1078-0432.CCR-11-3090
34. Del Poeta G, Postorino M, Pupo L et al (2016) Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs Today 52:249–260. https://doi.org/10.1358/dot.2016.52.4.2470954
35. Inoue-Yamauchi A, Jeng PS, Kim K et al (2017) Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun 8:16078. https://doi.org/10.1038/ncomms16078
36. Or CR, Chang Y, Lin WC et al. (2016) Obatoclax, a pan-BCL-2 inhibitor, targets cyclin D1 for degradation to induce antiproliferation in human colorectal carcinoma cells. Int J Mol Sci 18. https://doi.org/10.3390/ijms18010044
37. Oki Y, Copeland A, Hagemeister F et al (2012) Experience with obatoclax mesylate (GX15–070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119:2171–2172. https://doi.org/10.1182/blood-2011-11-391037
38. Safa AR (2016) Resistance to cell death and its modulation in cancer stem cells. Crit Rev Oncog 21:203–219. https://doi.org/10.1615/CritRevOncog.2016016976
39. Burton TR, Eisenstat DD, Gibson SB (2009) BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J Neurosci 29:4189–4199. https://doi.org/10.1523/JNEUROSCI.5747-08.2009
40. Li F, Zhang J, Arfuso F et al (2015) NF-κB in cancer therapy. Arch Toxicol 89:711–731. https://doi.org/10.1007/s00204-015-1470-4
41. Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K (2013) Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 3:120. https://doi.org/10.3389/fonc.2013.00120
42. Douer D (2003) Arsenic trioxide (Trisenox(R)) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 8:132–140. https://doi.org/10.1634/theoncologist.8-2-132
43. Shono Y, Tuckett AZ, Liou HC et al (2016) Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-kB-controlled oxidative stress responses. Cancer Res 76:377–389. https://doi.org/10.1158/0008-5472.CAN-14-2814
44. Fabre C, Mimura N, Bobb K et al (2012) Dual inhibition of canonical and noncanonical NF-kB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 18:4669–4681. https://doi.org/10.1158/1078-0432.CCR-12-0779
45. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K (2008) Inactivation of NF-kB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 51:5780–5788. https://doi.org/10.1021/jm8006245
46. Vaisitti T, Gaudino F, Ouk S et al (2017) Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-kappaB inhibitor. Haematologica 102:1878–1889. https://doi.org/10.3324/haematol.2017.173419
47. Blakely CM, Pazarentzos E, Olivas V et al (2015) NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep 11:98–110. https://doi.org/10.1016/j.celrep.2015.03.012
48. Hughes MA, Powley IR, Jukes-Jones R et al (2016) Co-operative and hierarchical binding of c-FLIP and caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol Cell 61:834–849. https://doi.org/10.1016/j.molcel.2016.02.023
49. Longley DB, Wilson TR, McEwan M et al (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25:838–848. https://doi.org/10.1038/sj.onc.1209122
50. Schinske KA, Nyati S, Khan AP et al (2011) A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-kappaB. Mol Cancer Ther 10:1807–1817. https://doi.org/10.1158/1535-7163.MCT-11-0362
51. Ramos-Miguel A, Garcia-Fuster MJ, Callado LF, La Harpe R, Meana JJ, Garcia-Sevilla JA (2009) Phosphorylation of FADD (Fas-associated death domain protein) at serine 194 is increased in the prefrontal cortex of opiate abusers: relation to mitogen activated protein kinase, phosphoprotein enriched in astrocytes of 15 kDa, and Akt signaling pathways involved in neuroplasticity. Neuroscience 161:23–38. https://doi.org/10.1016/j.neuroscience.2009.03.028
52. Nitulescu GM, Margina D, Juzenas P et al (2016) Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (review). Int J Oncol 48:869–885. https://doi.org/10.3892/ijo.2015.3306
53. Yap TA, Yan L, Patnaik A et al (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688–4695. https://doi.org/10.1200/JCO.2011.35.5263
54. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464. https://doi.org/10.1038/sj.onc.1209085
55. Oki Y, Fanale M, Romaguera J et al (2015) Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171:463–470. https://doi.org/10.1111/bjh.13603
56. Ghobrial IM, Roccaro A, Hong F et al (2010) Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin Cancer Res 16:1033–1041. https://doi.org/10.1158/1078-0432.CCR-09-1837
57. Pal SK, Reckamp K, Yu H, Figlin RA (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19:1355–1366. https://doi.org/10.1517/13543784.2010.520701
58. Porta C, Paglino C, Mosca A (2014) Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4:64. https://doi.org/10.3389/fonc.2014.00064
59. Henson E, Chen Y, Gibson S (2017) EGFR family members’ regulation of autophagy is at a crossroads of cell survival and death in cancer. Cancers. https://doi.org/10.3390/cancers9040027
60. Wei Y, Zou Z, Becker N et al (2013) EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 154:1269–1284. https://doi.org/10.1016/j.cell.2013.08.015
61. Ying WZ, Zhang HG, Sanders PW (2007) EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. J Am Soc Nephrol 18:131–142. https://doi.org/10.1681/ASN.2006040333
62. Patrick A, Blevins M, Krueger A et al (2014) Abstract B102: targeting the SIX1/EYA transcriptional complex as a potential anti-cancer therapy. Mol Cancer Ther 12:B102-B102. https://doi.org/10.1158/1535-7163.targ-13-b102
63. Wang H, Li X, Liu H et al (2016) Six1 induces protein synthesis signaling expression in duck myoblasts mainly via up-regulation of mTOR. Genet Mol Biol 39:151–161. https://doi.org/10.1590/1678-4685-GMB-2015-0075
64. Armat M, Bakhshaiesh TO, Sabzichi M et al (2016) The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. Bosn J Basic Med Sci 16:28–34. https://doi.org/10.17305/bjbms.2016.674
65. Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL (2015) The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin Ther Targets 19:213–225. https://doi.org/10.1517/14728222.2014.978860
66. Zeng J, Liu D, Qiu Z et al (2014) GSK3beta overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS ONE 9:e91231. https://doi.org/10.1371/journal.pone.0091231
67. Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
68. Jego G, Hazoume A, Seigneuric R, Garrido C (2013) Targeting heat shock proteins in cancer. Cancer Lett 332:275–285. https://doi.org/10.1016/j.canlet.2010.10.014
69. Chatterjee S, Burns TF. (2017) Targeting heat shock proteins in cancer: a promising therapeutic approach. Int J Mol Sci 18. https://doi.org/10.3390/ijms18091978
70. Sakamoto H, Mashima T, Yamamoto K, Tsuruo T (2002) Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J Biol Chem 277:45770–45775. https://doi.org/10.1074/jbc.M207485200
71. Oba M, Yano S, Shuto T, Suico M, Eguma A, Kai H (2008) IFN-γ down-regulates Hsp27 and enhances hyperthermia-induced tumor cell death in vitro and tumor suppression in vivo. Int J Oncol. https://doi.org/10.3892/ijo.32.6.1317
72. Paoli P, Giannoni E, Chiarugi P (2013) Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833:3481–3498. https://doi.org/10.1016/j.bbamcr.2013.06.026
73. Su Z, Yang Z, Xie L, DeWitt JP, Chen Y (2016) Cancer therapy in the necroptosis era. Cell Death Differ 23:748–756. https://doi.org/10.1038/cdd.2016.8
74. Lalaoui N, Brumatti G (2017) Relevance of necroptosis in cancer. Immunol Cell Biol 95:137–145. https://doi.org/10.1038/icb.2016.120
75. Seo J, Lee E-W, Song J (2016) New role of E3 ubiquitin ligase in the regulation of necroptosis. BMB Reports 49:247–248. https://doi.org/10.5483/BMBRep.2016.49.5.067
76. Seo J, Lee E-W, Sung H et al (2016) CHIP controls necroptosis through ubiquitylation- and lysosome-dependent degradation of RIPK3. Nat Cell Biol 18:291–302. https://doi.org/10.1038/ncb3314
77. Osborn SL, Diehl G, Han SJ et al (2010) Fas-associated death domain (FADD) is a negative regulator of T-cell receptor-mediated necroptosis. Proc Natl Acad Sci USA 107:13034–13039. https://doi.org/10.1073/pnas.1005997107
78. Yang YP, Hu LF, Zheng HF et al (2013) Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin 34:625–635. https://doi.org/10.1038/aps.2013.5
79. Polivka J Jr, Janku F (2014) Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142:164–175. https://doi.org/10.1016/j.pharmthera.2013.12.004
80. Liang C (2010) Negative regulation of autophagy. Cell Death Differ 17:1807–1815. https://doi.org/10.1038/cdd.2010.115
81. Atkins MB, Yasothan U, Kirkpatrick P (2009) Everolimus. Nat Rev Drug Discov 8:535–536. https://doi.org/10.1038/nrd2924
82. Popovics P, Frigo DE, Schally AV, Rick FG (2015) Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. Expert Opin Ther Targets 19:617–632. https://doi.org/10.1517/14728222.2015.1005603
83. Rehman G, Shehzad A, Khan AL, Hamayun M (2014) Role of AMP-activated protein kinase in cancer therapy. Arch Pharm 347:457–468. https://doi.org/10.1002/ardp.201300402
84. Faubert B, Boily G, Izreig S et al (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17:113–124. https://doi.org/10.1016/j.cmet.2012.12.001
85. Melosky B (2014) Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol 4:244. https://doi.org/10.3389/fonc.2014.00244
86. Yang WS, SriRamaratnam R, Welsch ME et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317–331. https://doi.org/10.1016/j.cell.2013.12.010
87. Dixon SJ, Stockwell BR (2014) The role of iron and reactive oxygen species in cell death. Nat Chem Biol 10:9–17. https://doi.org/10.1038/nchembio.1416
88. Ma S, Henson ES, Chen Y, Gibson SB (2016) Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis 7:e2307. https://doi.org/10.1038/cddis.2016.208
89. Drakes ML, Stiff PJ (2014) Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther 3:151–165. https://doi.org/10.2147/ITT.S37790
90. Weiner LM, Murray JC, Shuptrine CW (2012) Antibody-based immunotherapy of cancer. Cell 148:1081–1084. https://doi.org/10.1016/j.cell.2012.02.034
91. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY (2013) Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119:421–475. https://doi.org/10.1016/B978-0-12-407190-2.00007-1
92. Wilken JA, Webster KT, Maihle NJ (2010) Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J Ovarian Res 3:7. https://doi.org/10.1186/1757-2215-3-7
93. Sotelo MJ, Garcia-Paredes B, Aguado C, Sastre J, Diaz-Rubio E (2014) Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 20:4208–4219. https://doi.org/10.3748/wjg.v20.i15.4208
94. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287. https://doi.org/10.1038/nrc3236
95. Patel SB, Gill D, Garrido-Laguna I (2016) Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther 9:75–86. https://doi.org/10.2147/OTT.S68558
96. Garnock-Jones KP, Keating GM, Scott LJ (2010) Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70:215–239. https://doi.org/10.2165/11203700-000000000-00000
97. Rodriguez PC, Popa X, Martinez O et al (2016) A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 22:3782–3790. https://doi.org/10.1158/1078-0432.CCR-15-0855
98. Saavedra D, Crombet T (2017) CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol 8:269. https://doi.org/10.3389/fimmu.2017.00269
99. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR (2007) Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 57:365–372. https://doi.org/10.1016/j.lungcan.2007.04.002
100. Tanaka T, Kitamura H, Inoue R et al. (2013) Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer—results from phase I clinical trials. Clin Dev Immunol 2013:262967. https://doi.org/10.1155/2013/262967
101. Fenstermaker RA, Ciesielski MJ, Qiu J et al (2016) Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother 65:1339–1352. https://doi.org/10.1007/s00262-016-1890-x
102. Li R, Qian J, Zhang W et al (2014) Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma. Br J Haematol 166:690–701. https://doi.org/10.1111/bjh.12943
103. Bloch O, Crane CA, Fuks Y et al (2014) Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 16:274–279. https://doi.org/10.1093/neuonc/not203
104. Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6:140–146. https://doi.org/10.1016/j.molonc.2012.01.010
105. Ward TH, Cummings J, Dean E et al (2008) Biomarkers of apoptosis. Br J Cancer 99:841–846. https://doi.org/10.1038/sj.bjc.6604519
106. Krysan K, Dalwadi H, Sharma S, Pold M, Dubinett S (2004) Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64:6359–6362. https://doi.org/10.1158/0008-5472.CAN-04-1681
107. Olsen D, Jorgensen JT (2014) Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol 4:105. https://doi.org/10.3389/fonc.2014.00105
108. Punnoose EA, Leverson JD, Peale F et al (2016) Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist Venetoclax in multiple myeloma models. Mol Cancer Ther 15:1132–1144. https://doi.org/10.1158/1535-7163.MCT-15-0730
109. Khalil AA, Kabapy NF, Deraz SF, Smith C (2011) Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta 1816:89–104. https://doi.org/10.1016/j.bbcan.2011.05.001
110. Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86. https://doi.org/10.1379/CSC-99r.1
111. Del Gaizo Moore V, Letai A (2013) BH3 profiling—measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332:202–205. https://doi.org/10.1016/j.canlet.2011.12.021
112. Callagy GM, Pharoah PD, Pinder SE et al (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12:2468–2475. https://doi.org/10.1158/1078-0432.CCR-05-2719
113. Yoshino T, Shiina H, Urakami S et al (2006) Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12:6116–6124. https://doi.org/10.1158/1078-0432.CCR-06-0147
114. Jaiswal PK, Goel A, Mittal RD (2015) Survivin: a molecular biomarker in cancer. Indian J Med Res 141:389–397. https://doi.org/10.4103/0971-5916.159250
115. Seligson DB, Hongo F, Huerta-Yepez S et al (2007) Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 13:6056–6063. https://doi.org/10.1158/1078-0432.CCR-07-0960
116. Dutton A, Young LS, Murray PG (2006) The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets 10:27–35. https://doi.org/10.1517/14728222.10.1.27
117. Korkolopoulou P, Saetta AA, Levidou G et al (2007) c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 51:150–156. https://doi.org/10.1111/j.1365-2559.2007.02723.x
118. Schrijvers ML, Pattje WJ, Slagter-Menkema L et al (2012) FADD expression as a prognosticator in early-stage glottic squamous cell carcinoma of the larynx treated primarily with radiotherapy. Int J Radiat Oncol Biol Phys 83:1220–1226. https://doi.org/10.1016/j.ijrobp.2011.09.060
119. Kurozumi S, Yamaguchi Y, Hayashi S et al (2016) Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med 5:1873–1882. https://doi.org/10.1002/cam4.780
120. Liang ZL, Kim M, Huang SM, Lee HJ, Kim JM (2013) Expression of carboxyl terminus of Hsp70-interacting protein (CHIP) indicates poor prognosis in human gallbladder carcinoma. Oncol Lett 5:813–818. https://doi.org/10.3892/ol.2013.1138
121. Owonikoko TK, Khuri FR (2013) Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. https://doi.org/10.1200/EdBook_AM.2013.33.e395
122. Zeng J, Shi R, Cai CX et al (2015) Increased expression of Six1 correlates with progression and prognosis of prostate cancer. Cancer Cell Int 15:63. https://doi.org/10.1186/s12935-015-0215-z
123. Guerriero E, Capone F, Accardo M et al (2015) GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues. Eur J Histochem 59:2540. https://doi.org/10.4081/ejh.2015.2540
124. Larrea E, Sole C, Manterola L et al. (2016) New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 17. https://doi.org/10.3390/ijms17050627
125. Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586. https://doi.org/10.1200/JCO.2012.45.2011
126. Oellerich M, Schutz E, Beck J et al (2017) Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci 54:205–218. https://doi.org/10.1080/10408363.2017.1299683
127. Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S (2012) Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol 19:S33–S44. https://doi.org/10.3747/co.19.1149
128. Page K, Hava N, Ward B et al (2011) Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 104:1342–1348. https://doi.org/10.1038/bjc.2011.89
129. Morin I, Dixon NE, Schaeffer PM (2010) Ultrasensitive detection of antibodies using a new Tus-Ter-lock immunoPCR system. Mol Biosyst 6:1173–1175. https://doi.org/10.1039/c002163f
130. Chang L, Li J, Wang L (2016) Immuno-PCR: an ultrasensitive immunoassay for biomolecular detection. Anal Chim Acta 910:12–24. https://doi.org/10.1016/j.aca.2015.12.039
131. Li K, Wu D, Chen X et al (2014) Current and emerging biomarkers of cell death in human disease. Biomed Res Int 2014:690103. https://doi.org/10.1155/2014/690103
132. Weigum SE, Floriano PN, Redding SW et al (2010) Nano-bio-chip sensor platform for examination of oral exfoliative cytology. Cancer Prev Res 3:518–528. https://doi.org/10.1158/1940-6207.CAPR-09-0139
133. Morin I, Askin SP, Schaeffer PM (2011) IgG-detection devices for the Tus-Ter-lock immuno-PCR diagnostic platform. Analyst 136:4815–4821. https://doi.org/10.1039/c1an15731k
134. Dahdah DB, Morin I, Moreau MJ, Dixon NE, Schaeffer PM. (2009) Site-specific covalent attachment of DNA to proteins using a photoactivatable Tus-Ter complex. Chem Commun (Camb):3050–3052. https://doi.org/10.1039/b900905a
135. Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM (2016) Biomarkers for Immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Book 35:e493–e503. https://doi.org/10.14694/EDBK_160766
136. Qiu H, Fang X, Luo Q, Ouyang G (2015) Cancer stem cells: a potential target for cancer therapy. Cell Mol Life Sci 72:3411–3424. https://doi.org/10.1007/s00018-015-1920-4
137. Signore M, Ricci-Vitiani L, De Maria R (2013) Targeting apoptosis pathways in cancer stem cells. Cancer Lett 332:374–382. https://doi.org/10.1016/j.canlet.2011.01.013
138. Giampazolias E, Zunino B, Dhayade S et al (2017) Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol 19:1116–1129. https://doi.org/10.1038/ncb3596
139. Hannes S, Abhari BA, Fulda S (2016) Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. Cancer Lett 380:31–38. https://doi.org/10.1016/j.canlet.2016.05.036
140. Lopez JS, Banerji U (2017) Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 14:57–66. https://doi.org/10.1038/nrclinonc.2016.96
141. Ricci MS, Zong WX (2006) Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11:342–357. https://doi.org/10.1634/theoncologist.11-4-342
142. Grazia G, Penna I, Perotti V, Anichini A, Tassi E (2014) Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol 45:929–949. https://doi.org/10.3892/ijo.2014.2491